Immune regulatory properties and interactions of Copolymer-I and beta-interferon 1a in multiple sclerosis

被引:23
作者
Zang, Y
Hong, J
Robinson, R
Li, SF
Rivera, VM
Zhang, JWZ
机构
[1] Baylor Coll Med, Dept Neurol, Multiple Sclerosis Res Unit, Houston, TX 77030 USA
[2] Baylor Coll Med, Baylor Multiple Sclerosis Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA
关键词
copolymer-1; interferon beta; multiple sclerosis; T cell regulation;
D O I
10.1016/S0165-5728(03)00049-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The treatment efficacy of beta-interferon (beta-IFN) and Copolymer-1 (COP-1) for multiple sclerosis (MS) is potentially attributable to the immune regulatory properties of the drugs. In this study, we compared the regulatory effects of beta-IFN-1a and COP-1 used individually and in combination on the function of T cells derived from MS patients and healthy controls. The results revealed that the two drugs regulated predominantly CD4+ T cells with distinct properties. COP-1 activated both Th1 and Th2 cells while beta-IFN-1a was generally suppressive for Th1 cells and up-regulated IL-10 production. Furthermore, both drugs seemed to alter the T cell responses to myelin basic protein (MBP), a candidate myelin autoantigen for MS. The most significant finding is that COP-1 and beta-IFN-1a act individually through distinct regulatory properties and interact antagonistically when they are combined. The study has important clinical implications in the planned clinical trials to test treatment efficacy of combination therapy. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 42 条
[1]   Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking [J].
Aharoni, R ;
Teitelbaum, D ;
Arnon, R ;
Sela, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (02) :634-639
[2]   Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis [J].
Aharoni, R ;
Teitelbaum, D ;
Sela, M ;
Arnon, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10821-10826
[3]   The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease [J].
BenNun, A ;
Mendel, I ;
Bakimer, R ;
FridkisHareli, M ;
Teitelbaum, D ;
Arnon, R ;
Sela, M ;
deRosbo, NK .
JOURNAL OF NEUROLOGY, 1996, 243 (04) :S14-S22
[4]  
Brod SA, 2000, ANN NEUROL, V47, P127, DOI 10.1002/1531-8249(200001)47:1<127::AID-ANA22>3.0.CO
[5]  
2-1
[6]  
Comi G, 2001, NEUROLOGY, V56, pA255
[7]   European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis [J].
Comi, G ;
Filippi, M ;
Wolinsky, JS .
ANNALS OF NEUROLOGY, 2001, 49 (03) :290-297
[8]   Glatiramer acetate (copolymer-1)-specific, human T cell lines:: cytokine profile and suppression of T cell lines reactive against myelin basic protein [J].
Dabbert, D ;
Rösner, S ;
Krämer, M ;
Schöll, U ;
Tumani, H ;
Mäder, M ;
Weber, F .
NEUROSCIENCE LETTERS, 2000, 289 (03) :205-208
[9]   Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis [J].
Duda, PW ;
Schmied, MC ;
Cook, SL ;
Krieger, JI ;
Hafler, DA .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (07) :967-976
[10]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661